Angiotensin-(1–9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Little is known about the biological effects of angiotensin-(1-9), but available evidence shows that angiotensin-(1-9) has beneficial effects in preventing/ameliorating cardiovascular remodeling. OBJECTIVE: In this study, we evaluated whether angiotensin-(1-9) decreases hypertension and reverses experimental cardiovascular damage in the rat. METHODS AND RESULTS: Angiotensin-(1-9) (600 ng/kg per min for 2 weeks) reduced already-established hypertension in rats with early high blood pressure induced by angiotensin II infusion or renal artery clipping. Angiotensin-(1-9) also improved cardiac (assessed by echocardiography) and endothelial function in small-diameter mesenteric arteries, cardiac and aortic wall hypertrophy, fibrosis, oxidative stress, collagen and transforming growth factor type β - 1 protein expression (assessed by western blot). The beneficial effect of angiotensin-(1-9) was blunted by coadministration of the angiotensin type 2(AT2) receptor blocker PD123319 (36 ng/kg per min) but not by coadministration of the Mas receptor blocker A779 (100 ng/kg per min). Angiotensin-(1-9) treatment also decreased circulating levels of Ang II, angiotensin-converting enzyme activity and oxidative stress in aorta and left ventricle. Whereas, Ang-(1-9) increased endothelial nitric oxide synthase mRNA levels in aorta as well as plasma nitrate levels. CONCLUSION: Angiotensin-(1-9) reduces hypertension, ameliorates structural alterations (hypertrophy and fibrosis), oxidative stress in the heart and aorta and improves cardiac and endothelial function in hypertensive rats. These effects were mediated by the AT2 receptor but not by the angiotensin-(1-7)/Mas receptor axis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature
Velázquez-Armenta, E. Y., Han, J. Y., Choi, J. S., Yang, K. M., & Nava-Ocampo, A. A. (2007) · Hypertension in Pregnancy · doi:10.1080/10641950601147937 · Cited by 33 · cited 1×
“AT2R is the predominant Ang II receptor subtype in the fetal and early postnatal period, and the absence of AT2R negatively affect cardiac and renal maturation and growth [35–37].”
Background
Cited by
Counter-regulatory renin–angiotensin system in cardiovascular disease
Paz Ocaranza, M., Riquelme, J. A., García, L., Jalil, J. E., Chiong, M., Santos, R. A. S., & Lavandero, S. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0244-8 · Cited by 561
Self-citationArendse, L. B., Danser, A. H. J., Poglitsch, M., Touyz, R. M., Burnett, J. C., Llorens-Cortes, C., Ehlers, M. R., & Sturrock, E. D. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017129 · Cited by 339
New approaches in the treatment of hypertension
Oparil, S., & Schmieder, R. E. (2015) · Circulation Research · doi:10.1161/circresaha.116.303603 · Cited by 276
The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target
Steckelings, U. M., Widdop, R. E., Sturrock, E. D., Lubbe, L., Hussain, T., Kaschina, E., Unger, T., Hallberg, A., Carey, R. M., & Sumners, C. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000281 · Cited by 97
Renin–Angiotensin–Aldosterone System and Immunomodulation: A State-of-the-Art Review
Laghlam, D., Jozwiak, M., & Nguyen, L. S. (2021) · Cells · doi:10.3390/cells10071767 · Cited by 96
“Angiotensin 1–7 binds to the protooncogen as receptor, which leads to vasodilation, antihypertensive, and antifibrosis effects [3], while Ang 1–9 can activate AT2R to trigger natriuresis and production, thus ediating vasodilatory effects and reducing blood pressure [4].”
Background
Metadata
- Authors
- Ocaranza, M. P., Moya, J., Barrientos, V., Alzamora, R., Hevia, D., Morales, C., Pinto, M., Escudero, N., García, L., Novoa, U., Ayala, P., Díaz-Araya, G., Godoy, I., Chiong, M., Lavandero, S., Jalil, J. E., & Michea, L.
- Venue
- Journal of Hypertension
- Published
- 2014-04
- Volume
- 32
- Issue
- 4
- Pages
- 771-783
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W2334691550
- Cited by
- 99
- References
- 1
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Angiotensin-(1–9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis. https://app.cochat.ai/papers/10.1097/hjh.0000000000000094
- The paper
- Ocaranza, M. P., Moya, J., Barrientos, V., Alzamora, R., Hevia, D., Morales, C., Pinto, M., Escudero, N., García, L., Novoa, U., Ayala, P., Díaz-Araya, G., Godoy, I., Chiong, M., Lavandero, S., Jalil, J. E., & Michea, L. (2014). Angiotensin-(1–9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis. Journal of Hypertension. https://doi.org/10.1097/hjh.0000000000000094
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.